
Alphatec Hlds (ATEC) Stock Forecast & Price Target
Alphatec Hlds (ATEC) Analyst Ratings
Bulls say
Alphatec Holdings is viewed positively because its core spine surgery franchise is still posting strong operating momentum, with 1Q26 surgery revenue of $178M up 17% year over year, case volume up 21%, and net new surgeon users up 23%. Even with EOS softness and a 17.6% decline in EOS sales, the company delivered 71.0% gross margin, $20.7M in adjusted EBITDA, and disciplined OpEx that supported affirmed profitability guidance and $11M of free cash use near the favorable end of its 1Q guide. The outlook is further strengthened by management’s execution in Japan, the potential of PTP and LTP, and new product catalysts such as Valence and OsteoAdapt, which could expand the portfolio and sustain above-peer growth into 2026 and 2027.
Bears say
Alphatec Holdings is facing a negative setup because 1Q26 revenue of $192M missed consensus by $5M and EPS loss of $0.22 was far worse than the $0.02 loss expected, underscoring weak execution. The main drag was EOS imaging, where sales fell 18% year over year to $14M on poor sales execution and missed hardware installs, forcing management to cut 2026 revenue guidance to $882M from $890M. Although adjusted EBITDA guidance of $134M and free cash flow of $20M were reiterated, the reduced top line, mix pressure from Cervical and OUS growth, and ongoing spine-market pricing and regulatory risks leave the outlook fragile.
This aggregate rating is based on analysts' research of Alphatec Hlds and is not a guaranteed prediction by Public.com or investment advice.
Alphatec Hlds (ATEC) Analyst Forecast & Price Prediction
Start investing in Alphatec Hlds (ATEC)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Alphatec Hlds (ATEC) Forecast
Alphatec Hlds (ATEC) Analyst Forecast & Price Prediction
Start investing in Alphatec Hlds (ATEC)
Order type
Buy in
Order amount
Est. shares
0 shares